Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Suramin-induced neutropenia

N A Dawson¹, R M Lush, S M Steinberg

¹Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland, USA.

European Journal of Cancer (Oxford, England : 1990)

|August 1, 1996

Summary

Severe neutropenia (low white blood cell count) from suramin is unpredictable but resolves quickly with granulocyte-colony stimulating factor (G-CSF) treatment, allowing continued suramin therapy.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.

ESMO open·2025

Same author

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.

ESMO open·2021

Same author

ANG1005 for breast cancer brain metastases: correlation between <sup>18</sup>F-FLT-PET after first cycle and MRI in response assessment.

Breast cancer research and treatment·2016

Same author

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

International journal of cancer·2016

Same author

Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD.

Bone marrow transplantation·2016

Same author

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Area of Science:

Oncology
Pharmacology
Hematology

Background:

Suramin is a drug used in treating certain cancers.
Severe neutropenia is a potential side effect of suramin therapy.
Understanding the mechanism and management of suramin-induced neutropenia is crucial for patient safety.